Radiosensitizing nucleosides.
Radiosensitizing nucleosides.
复制标题
放射增敏核苷。
DOI：
10.1093/jnci/88.17.1193
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
Lawrence,TS
中科院分区：
文献类型：
--
作者：
McGinn,CJ;Shewach,DS;Lawrence,TS
扰乱核苷酸代谢的化疗药物有可能使肿瘤细胞对放射治疗产生实质性的敏化。这个过程被称为放射致敏，引起它的药剂被称为放射致敏剂。氟嘧啶作为放射增敏剂的临床有效性已在多个随机试验中得到证实。胸苷类似物和羟基脲似乎也会产生临床相关的辐射敏感性增加。最近的实验室调查已确定二氟脱氧胞苷（吉西他滨）和氟达拉滨是有希望与放射联合使用的药物。直到最近，人们对这些药物引起的生化变化是如何产生放射致敏的还知之甚少。然而，相关领域的进展，如细胞周期检查点控制，已经允许发展一种假设，可以解释氟嘧啶介导的放射致敏的相对肿瘤选择性。此外，最近的研究结果表明，合理操纵给药时间表和使用放射增敏剂的组合有可能提高目前使用的药物的疗效，并确定新药物的益处。[J] contemporary medicine; 2009；88:1193 - 1203]
Chemotherapeutic drugs that perturb nucleotide metabolism have the potential to produce substantial sensitization of tumor cells to radiation treatment. The process is called radiosensitization, and the agents that induce it are called radiosensitizers. The clinical effectiveness of fluoropyrimidines as radiosensitizers has been proven in multiple randomized trials. Thymidine analogues and hydroxyurea also appear to produce clinically relevant increases in radiation sensitivity. Recent laboratory investigations have identified difluorodeoxycytidine (gemcitabine) and fludarabine as promising agents to use in combination with radiation. Until recently, little was known about how the biochemical changes caused by these drugs produced radiosensitization. However, advances in related fields, such as cell cycle checkpoint control, have permitted the development of a hypothesis that may explain the relative tumor selectivity of fluoropyrimidine-mediated radiosensitization. In addition, recent findings suggest that the rational manipulation of drug administration schedules and the use of combinations of radiosensitizers have the potential to improve the efficacy of the currently used agents and to establish the benefit of new ones. [J Natl Cancer Inst 1996;88:1193–1203]